In Vitro and In Vivo Efficacy of DNA Damage Repair Inhibitor Veliparib in Combination with Artesunate against Echinococcus granulosus

Figure 4

In vivo efficacy response of Veliparib in combination with AS in cystic echinococcosis models. (a) After euthanasia, the cysts were resected and weighed. Data consists of 10 mice per treatment group; bars, SE. For statistical analysis and being compared with the model group, ^B. (b) TEM analyses of the cystic wall after in vivo treatment with ABZ, AS-H, and AS-H+Veliparib. The CMC-treated cystic walls showed that the germinal layer (gl) and clearly visible cells were undifferentiated cells (c) and the microtriches (mt) protruded from the tegument wall to laminated layer. Representative micrographs of the cystic wall collected from the infected Kunming mice after the daily lavage of ABZ (200 mg/kg/d), AS-H (200 mg/kg/d), and AS-H (200 mg/kg/d)+Veliparib (25 mg/kg/d). l: lipid droplets; v: vacuoles; V: Veliparib.

(a)

(b)